Reasons for Gary King’s Shares Sale of Myriad Genetics, Inc. (MYGN)’s Stock; Epizyme (EPZM) Shorts Lowered By 1.61%

Gary King, the Exec. VP International Ops of Myriad Genetics Inc made insider trade for 34,445 shares with an average price-per-share of $39.7 in the Pinksheet-listed company, that are having a worth of $1,366,588 U.S. Dollars. Gary is trying to quietly decrease his company’s share, same as he did in the last 30 days. He sold another 3,120 shares worth $118,934 USD. At the moment, Gary King holds 121,968 shares or 0.18% of Myriad Genetics Inc’s total market cap.

Epizyme Incorporated (NASDAQ:EPZM) had a decrease of 1.61% in short interest. EPZM’s SI was 5.66M shares in January as released by FINRA. Its down 1.61% from 5.75M shares previously. With 468,200 avg volume, 12 days are for Epizyme Incorporated (NASDAQ:EPZM)’s short sellers to cover EPZM’s short positions. The SI to Epizyme Incorporated’s float is 15.71%. The stock increased 7.54% or $1.15 during the last trading session, reaching $16.4. About 666,759 shares traded or 33.01% up from the average. Epizyme, Inc. (NASDAQ:EPZM) has risen 91.85% since January 23, 2017 and is uptrending. It has outperformed by 75.15% the S&P500.

Investors sentiment decreased to 1.46 in Q3 2017. Its down 0.47, from 1.93 in 2017Q2. It dived, as 15 investors sold Epizyme, Inc. shares while 22 reduced holdings. 13 funds opened positions while 41 raised stakes. 58.04 million shares or 22.28% more from 47.46 million shares in 2017Q2 were reported. Renaissance Technology Lc invested 0.01% in Epizyme, Inc. (NASDAQ:EPZM). Morgan Stanley has invested 0% in Epizyme, Inc. (NASDAQ:EPZM). Woodstock invested in 31,766 shares. Moreover, Pacad Limited has 0.02% invested in Epizyme, Inc. (NASDAQ:EPZM) for 4,000 shares. Federated Pa holds 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 43,020 shares. 1.04 million were accumulated by Franklin. Bain Public Equity Mngmt Limited Liability Company invested 0.22% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM). Comml Bank Of Ny Mellon has 0% invested in Epizyme, Inc. (NASDAQ:EPZM). Great West Life Assurance Can owns 4,800 shares or 0% of their US portfolio. Ubs Asset Mgmt Americas reported 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM). Aqr Capital Management Ltd Com, a Connecticut-based fund reported 32,692 shares. California Employees Retirement has invested 0% in Epizyme, Inc. (NASDAQ:EPZM). 43,274 were reported by Nationwide Fund Advsrs. Redmile Gp Ltd invested 1.14% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM). Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 988 shares in its portfolio.

Since August 24, 2017, it had 1 insider purchase, and 3 sales for $2.32 million activity. MOTT DAVID M bought 200,000 shares worth $3.05M. Ho Peter Tai-Ching sold $252,077 worth of stock.

Among 12 analysts covering Epizyme (NASDAQ:EPZM), 11 have Buy rating, 0 Sell and 1 Hold. Therefore 92% are positive. Epizyme had 29 analyst reports since August 6, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of EPZM in report on Monday, June 12 with “Buy” rating. The firm earned “Buy” rating on Friday, August 4 by RBC Capital Markets. The rating was maintained by Cowen & Co on Wednesday, June 7 with “Buy”. The rating was maintained by H.C. Wainwright on Thursday, June 15 with “Buy”. The stock of Epizyme, Inc. (NASDAQ:EPZM) earned “Outperform” rating by RBC Capital Markets on Monday, September 28. The firm has “Buy” rating by Oppenheimer given on Wednesday, June 14. H.C. Wainwright upgraded Epizyme, Inc. (NASDAQ:EPZM) rating on Monday, March 14. H.C. Wainwright has “Buy” rating and $25 target. The stock of Epizyme, Inc. (NASDAQ:EPZM) has “Buy” rating given on Friday, October 27 by SunTrust. The stock has “Buy” rating by Oppenheimer on Monday, June 5. The company was downgraded on Tuesday, August 25 by Zacks.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.14 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

The stock increased 3.26% or $1.26 during the last trading session, reaching $39.88. About 1.17 million shares traded or 34.60% up from the average. Myriad Genetics, Inc. (NASDAQ:MYGN) has declined 37.47% since January 23, 2017 and is downtrending. It has underperformed by 54.17% the S&P500.

Among 20 analysts covering Myriad Genetics (NASDAQ:MYGN), 4 have Buy rating, 4 Sell and 12 Hold. Therefore 20% are positive. Myriad Genetics has $52 highest and $15 lowest target. $33.50’s average target is -16.00% below currents $39.88 stock price. Myriad Genetics had 52 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Tuesday, August 8 by Piper Jaffray. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Underweight” rating given on Wednesday, August 10 by Morgan Stanley. Piper Jaffray maintained Myriad Genetics, Inc. (NASDAQ:MYGN) rating on Tuesday, September 15. Piper Jaffray has “Overweight” rating and $45 target. The company was maintained on Tuesday, January 2 by Stephens. The stock of Myriad Genetics, Inc. (NASDAQ:MYGN) has “Sell” rating given on Monday, October 10 by Ladenburg Thalmann. The company was downgraded on Wednesday, November 2 by Stephens. The rating was maintained by Avondale with “Market Outperform” on Wednesday, May 4. The firm has “Hold” rating by Piper Jaffray given on Sunday, October 15. The firm has “Hold” rating given on Wednesday, August 10 by Gabelli. Deutsche Bank initiated Myriad Genetics, Inc. (NASDAQ:MYGN) rating on Thursday, January 7. Deutsche Bank has “Buy” rating and $52 target.

Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company has market cap of $2.76 billion. The firm offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It has a 26.45 P/E ratio. It also provides COLARIS, a DNA sequencing test for colorectal and uterine cancer; COLARIS AP, a DNA sequencing test for colorectal cancer; Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; and EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer.

Analysts await Myriad Genetics, Inc. (NASDAQ:MYGN) to report earnings on February, 6. They expect $0.24 EPS, down 7.69% or $0.02 from last year’s $0.26 per share. MYGN’s profit will be $16.62M for 41.54 P/E if the $0.24 EPS becomes a reality. After $0.26 actual EPS reported by Myriad Genetics, Inc. for the previous quarter, Wall Street now forecasts -7.69% negative EPS growth.

Investors sentiment decreased to 0.86 in Q3 2017. Its down 0.16, from 1.02 in 2017Q2. It dropped, as 33 investors sold Myriad Genetics, Inc. shares while 72 reduced holdings. 28 funds opened positions while 62 raised stakes. 71.79 million shares or 8.95% less from 78.85 million shares in 2017Q2 were reported. Zebra Capital Mgmt reported 10,035 shares. Teacher Retirement Sys Of Texas owns 5,632 shares. Ameritas Invest invested in 0.01% or 5,525 shares. Glenmede Trust Na reported 0% in Myriad Genetics, Inc. (NASDAQ:MYGN). American Century reported 0% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN). Sterling Capital Management Limited Liability reported 7,249 shares stake. Paloma Prns Management holds 0% or 8,200 shares in its portfolio. The Minnesota-based Thrivent For Lutherans has invested 0.36% in Myriad Genetics, Inc. (NASDAQ:MYGN). Comerica Bank holds 0.03% or 120,117 shares in its portfolio. Credit Agricole S A has invested 0.02% in Myriad Genetics, Inc. (NASDAQ:MYGN). D E Shaw has 4.87 million shares for 0.27% of their portfolio. Consonance L P owns 7.9% invested in Myriad Genetics, Inc. (NASDAQ:MYGN) for 1.97 million shares. Bb&T Securities Ltd Liability, Virginia-based fund reported 11,338 shares. Moreover, Loomis Sayles Lp has 0% invested in Myriad Genetics, Inc. (NASDAQ:MYGN). Arizona State Retirement has invested 0.02% of its portfolio in Myriad Genetics, Inc. (NASDAQ:MYGN).